Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes

Doring, 2012, Treatment of lung infection in patients with cystic fibrosis: current and future strategies, J Cyst Fibros, 11, 461, 10.1016/j.jcf.2012.10.004

Mogayzel, 2013, Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health, Am J Respir Crit Care Med, 187, 680, 10.1164/rccm.201207-1160OE

Cystic Fibrosis Foundation Patient Registry, 2010

Cystic Fibrosis Foundation Patient Registry, 2013

VanDevanter, 2014, Incorporation of a third inhaled antipseudomonal antibiotic class into the management of patients at an adult CF care center, J Cyst Fibros, 13, S16, 10.1016/S1569-1993(14)60051-5

Wang, 1993, Pulmonary function between 6 and 18years of age, Pediatr Pulmonol, 15, 75, 10.1002/ppul.1950150204

Hankinson, 1999, Spirometric reference values from a sample of the general U.S. population, Am J Respir Crit Care Med, 159, 179, 10.1164/ajrccm.159.1.9712108

Micallef, 2014, eulerAPE: Drawing area-proportional 3-Venn diagrams using ellipses, PLoS ONE, 9, e101717, 10.1371/journal.pone.0101717

VanDevanter, 2011, Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis, Respir Med, 105, S18, 10.1016/S0954-6111(11)70023-3

Moskowitz, 2008, Shifting patterns of inhaled antibiotic use in cystic fibrosis, Pediatr Pulmonol, 43, 874, 10.1002/ppul.20873

Bresnik, 2012, Phase 3 study of aztreonam for inhalation solution (AZLI) in a continuous alternating therapy regimen for the treatment of chronic Pseudomonas aeruginosa infection in patients with CF (AZLI CAT)

VanDevanter, 2012, Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease, Clin Investig, 2, 163, 10.4155/cli.11.174